Investigational drug · Phase 3
CT001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pain.
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "CT001"
First trial start
2024
May 27, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CT001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pain
Approved drugs for the same conditions: Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "CT001" as an intervention, largest first.
- Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001Pivotal-lookingCompleted
Cessatech A/SIndustry
NCT05508594 · 220 participants · Start Sep 5, 2022 · Primary completion Oct 5, 2023
Drug: CT001; Placebo and 2 more · For: Pain
Sites: Copenhagen, Denmark
- Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric PatientsPivotal-lookingCompleted
Cessatech A/SIndustry
NCT06364072 · 155 participants · Start May 27, 2024 · Primary completion May 9, 2025
Drug: CT001 · For: Pain
Sites: Alicante, Spain; Barcelona, Spain; Madrid, Spain · 7 sites in all
iBio, Inc.Industry
NCT07487376 · 32 participants (planned) · Start May 24, 2026 · Primary completion May 2027
Drug: IBIO-600; Placebo · For: Overweight , Obesity
Sites: Bayswater, Australia
- Study of CT001 in Healthy VolunteersCompleted
Cessatech A/SIndustry
NCT04807335 · 14 participants · Start Mar 17, 2021 · Primary completion Jun 2, 2021
Drug: CT001; Ketamine and 1 more · For: Bioavailability
Sites: Copenhagen, Denmark
Newest research
PubMed records naming it or its code names, newest first.
- From phenotype to mechanism: background-dependent function of CtDnaJ.16 in thermotolerance-divergent Coriolopsis trogii haploids.
Wang L, Ma C, Zhao S, et al. · Front Microbiol 2026
- Rapid clearing CT-001 restored hemostasis in mice with coagulopathy induced by activated protein C.
Sim DS, Mallari CR, Bauzon M, et al. · J Trauma Acute Care Surg 2024
- CT-001, a novel fast-clearing factor VIIa, enhanced the hemostatic activity in postpartum samples.
Sim DS, Mallari CR, Hermiston TW, et al. · Blood Adv 2024
- CRISPR/Cas9-Mediated Mutagenesis of BrLEAFY Delays the Bolting Time in Chinese Cabbage (Brassica rapa L. ssp. pekinensis).
Shin YH, Park YD · Int J Mol Sci 2022
- CRISPR/Cas9-Mediated Editing of AGAMOUS-like Genes Results in a Late-Bolting Phenotype in Chinese Cabbage (Brassica rapa ssp. pekinensis).
Shin YH, Lee HM, Park YD · Int J Mol Sci 2022
- CT-001 is a rapid clearing factor VIIa with enhanced clearance and hemostatic activity for the treatment of acute bleeding in non-hemophilia settings.
Sim DS, Mallari CR, Teare JM, et al. · Thromb Res 2022
Also in development for Pain
- CebranopadolTRN-228Phase 34 trials
Adneuris Therapeutics, Inc. · Pain, Acute Pain, Chronic Pain
- Active Comparator: MorphinePhase 32 trials
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Pain
- MR-107A-02Phase 31 trial
Viatris Specialty LLC · Acute Pain, Post Operative Pain, Pain
- SRP-001Phase 21 trial
South Rampart Pharma, Inc. · Acute Pain, Postoperative Pain, Pain
- YZJ-4729Phase 21 trial
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Pain
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.